European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week

MT Newswires Live11-16

European equities traded in the US as American depositary receipts were moving lower late Friday morning, declining 0.85% to 1,302.64 on the S&P Europe Select ADR Index, which is down about 2.8% for the week.

From continental Europe, the gainers were led by financial services company Banco Bilbao Vizcaya Argentaria (BBVA) and pharmaceutical company Ascendis Pharma (ASND), which rose 3.2% and 2.7%, respectively. They were followed by biopharmaceutical company DBV Technologies (DBVT) and financial services company Banco Santander (SAN), which increased 2.3% and 2.2%, respectively.

The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company Cellectis (CLLS), which fell 9.3% and 6.8%, respectively. They were followed by biotech firm BioNTech (BNTX) and biopharmaceutical company argenx (ARGX), which lost 6.2% and 4.5%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company TC Biopharm (TCBP) and financial services company Lloyds Banking Group (LYG), which advanced 16% and 2%, respectively. They were followed by tobacco company British American Tobacco (BTI) and insurance company Prudential (PUK), which were up 1.9% and 1.5%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Biodexa Pharmaceuticals (BDRX), which tumbled 20% and 12%, respectively. They were followed by biopharmaceutical companies Mereo BioPharma Group (MREO) and Bicycle Therapeutics (BCYC), which dropped 5.7% and 5.5%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment